Leukemia, Myeloid: all 2,432 studies
Page 16 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02335814Phase 1
- Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid MalignanciesStatus unknownNCT02333838Phase 2
- A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic SyndromeStatus unknownNCT02328950
- A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AMLCompletedNCT02326584Phase 1
- Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 MutationsCompletedNCT02323607Phase 1
- Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02323022Phase 3
- Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02319135Phase 3
- Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid LeukemiaStatus unknownNCT02317159Phase 4
- Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02316964Phase 1
- Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative TherapyNo longer availableNCT02312037
- Study of Palbociclib in MLL-rearranged Acute LeukemiasStatus unknownNCT02310243Phase 1/2
- A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT02308761Phase 1
- Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AMLCompletedNCT02306291Phase 1/2
- A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)WithdrawnNCT02303782Phase 1/2
- Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02299518Phase 1
- Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 MutationsTerminatedNCT02298166Phase 3
- 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)CompletedNCT02283190Phase 1
- Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid LeukemiaCompletedNCT02282215Phase 2
- Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid LeukaemiaStatus unknownNCT02277847Phase 4
- Observational Trial of a Therapeutic Platelet Transfusion RegimenTerminatedNCT02276651
- Study of TCP-ATRA for Adult Patients With AML and MDSCompletedNCT02273102Phase 1
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsStatus unknownNCT02272478Phase 2/3
- A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDSTerminatedNCT02267863Phase 1
- Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
- Phase I, Dose Escalation Study of DecitabineCompletedNCT02264873Phase 1
- Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic TransplantationNo longer availableNCT02258490
- Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AMLTerminatedNCT02255162Phase 1
- Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic LeukemiaStatus unknownNCT02244658Phase 3
- Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic CancerStatus unknownNCT02240537Phase 1
- Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AMLWithdrawnNCT02238522Phase 1
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02236013Phase 1
- Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AMLTerminatedNCT02229266Phase 2
- Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell TransplantationCompletedNCT02226861Phase 1
- Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive ChemotherapyTerminatedNCT02226497Not applicable
- An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)TerminatedNCT02225574Phase 1
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
- Effect of 2nd Gen TKI in CMLCompletedNCT02222272
- Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDSCompletedNCT02221310Phase 2
- Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02215629Phase 1
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
- A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML PatientsTerminatedNCT02204722Phase 4
- Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDSWithdrawnNCT02204020Phase 2
- Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-LigandsCompletedNCT02203825Phase 1
- Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)TerminatedNCT02203773Phase 1
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
- Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedNCT02198482Phase 2
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDSCompletedNCT02190695Phase 2
- DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AMLCompletedNCT02182596Phase 1/2
- Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02181699Phase 1
- Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02181660Phase 1
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- Allogeneic SCT for CML, TKI Failure After TKI FailureStatus unknownNCT02172365
- Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid LeukemiaStatus unknownNCT02171117Phase 3
- LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia PatientsStatus unknownNCT02164903
- Vascular Dysfunction and Antiangiogenic TherapyCompletedNCT02161978
- Population Pharmacokinetics of Imatinib in CML Patients in IranTerminatedNCT02146846
- Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02141477Phase 1
- Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)Status unknownNCT02140606Phase 1
- Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AMLCompletedNCT02140242Phase 3
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
- Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDSStatus unknownNCT02124174Phase 2
- Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesCompletedNCT02122081Phase 1
- SCT Plus Immune Therapy in Average Risk AML/MDSCompletedNCT02117297Phase 2
- Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
- Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous LeukemiaWithdrawnNCT02115672Phase 1/2
- Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous LeukemiaCompletedNCT02113319Phase 2
- Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AMLTerminatedNCT02109627Phase 1
- Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CTCompletedNCT02103530Not applicable
- Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2/3
- A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.CompletedNCT02098967Phase 1
- Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02096289Phase 1
- Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02093403Phase 1
- Red Cell Transfusion Goals in Patients With Acute LeukemiasCompletedNCT02086773Phase 1
- Study of Molecular and Genetic Abnormalities in Patients With Myeloid NeoplasmsCompletedNCT02084563Phase 2
- Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantCompletedNCT02083250Phase 1
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedNCT02081378Phase 1
- Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AMLCompletedNCT02073838Phase 2
- Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid LeukemiaStatus unknownNCT02072811Phase 3
- Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02070458Phase 1
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
- Haplo-SCT vs ASCT With or Without Decitabine in AML CR1Status unknownNCT02059720Phase 3
- Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02057770Phase 1
- MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02049801Phase 1
- Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous LeukemiaTerminatedNCT02047149Phase 1
- A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AMLCompletedNCT02040506Phase 1
- Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)Status unknownNCT02034656
- Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid LeukemiaTerminatedNCT02034227Phase 1/2
- Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02029950Phase 1
- AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine ChemotherapyStatus unknownNCT02024308Phase 4
- Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.CompletedNCT02017457Phase 2
- A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid LeukemiaCompletedNCT02016729Phase 1
- Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)CompletedNCT02013648Phase 3
- Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single VaccinationStatus unknownNCT02007811Phase 1/2
- Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid LeukaemiaCompletedNCT02001818Phase 2
- LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous LeukemiaCompletedNCT01999556
- Observational Study of Patients Older Than 60 Years With Acute Myeloblastic LeukemiaStatus unknownNCT01966497
- Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01961765Phase 1
- Haploidentical NK-cell Infusion in Acute Myeloid LeukemiaCompletedNCT01947322Phase 1/2
- Safety Study of CPX-351 in Children With Relapsed Leukemia or LymphomaCompletedNCT01943682Phase 1